Associated Papers
Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.
Keller-Evans RB et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Functions, interactions and prognostic role of POLE: a bioinformatics analysis.
Carvajal-Veloza J et al.
Journal of Gynecologic Oncology, 2025
39575998 (PubMed )
Supplement: jgo-36-e45-s001.xls › jgo-36-e45-s001
Human DNA polymerase ε is a source of C>T mutations at CpG dinucleotides.
Tomkova M et al.
Nature Genetics, 2024
39390083 (PubMed )
Supplement: 41588_2024_1945_MOESM4_ESM.xlsx › Table6
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
37848928 (PubMed )
Supplement: 13073_2023_1234_MOESM3_ESM.xlsx › Table_S3
Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
Rocque MJ et al.
Molecular Genetics and Genomics : Mgg, 2023
Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S et al.
Journal of Gynecologic Oncology, 2022
35320887 (PubMed )
Supplement: jgo-33-e38-s001.xls › jgo-33-e38-s001
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
34586735 (PubMed )
Supplement: CTM2-11-e524-s001.xlsx › Supplementary_Table_2
Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A et al.
The Journal of Pathology, 2020
31829442 (PubMed )
Supplement: PATH-250-323-s002.xlsx › Supplementary_Table_S1
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
29604063 (PubMed )
Supplement: PATH-245-283-s020.xlsx › Figure.2.Drivers.Edited
Select a paper to view details